Ro-15-2041 is primarily used in scientific research as a selective antagonist for benzodiazepine binding sites on the GABAA receptor. It is employed to study the role of GABAergic neurotransmission in anxiety, memory, and sedation. Due to its ability to reverse the effects of benzodiazepines, it has been investigated for potential use in managing benzodiazepine overdose and tolerance. However, it remains an experimental compound and is not approved for clinical use. Its application is largely confined to preclinical studies in neuroscience and pharmacology.